GeoVax Labs, Inc. reported continued investment in advancing its lead GEO-MVA vaccine for orthopoxviruses, with a pivotal Phase 3 trial planned for the second half of 2026 targeting global shortages and biodefense needs. The company’s oncology candidate Gedeptin® and multi-antigen COVID-19 vaccine GEO-CM04S1 also progress through clinical stages, supported by expanding scientific advisory boards. GeoVax relies entirely on outsourced manufacturing with ongoing modernization efforts, which creates scale-up risks typical of small biotech firms. Financially, GeoVax reported a $21.5 million net loss in 2025 and holds approximately $3.1 million in cash as of mid-2026 amid a going concern opinion, underscoring reliance on additional capital raises and grant funding to sustain operations.